Logo image of ALNY

ALNYLAM PHARMACEUTICALS INC (ALNY) Stock Fundamental Analysis

NASDAQ:ALNY - Nasdaq - US02043Q1076 - Common Stock - Currency: USD

254.85  +3.29 (+1.31%)

After market: 254.85 0 (0%)

Fundamental Rating

3

ALNY gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 566 industry peers in the Biotechnology industry. While ALNY seems to be doing ok healthwise, there are quite some concerns on its profitability. ALNY is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

ALNY had negative earnings in the past year.
In the past year ALNY has reported a negative cash flow from operations.
In the past 5 years ALNY always reported negative net income.
ALNY had negative operating cash flow in 4 of the past 5 years.
ALNY Yearly Net Income VS EBIT VS OCF VS FCFALNY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200M -400M -600M -800M -1B

1.2 Ratios

The Return On Assets of ALNY (-6.56%) is better than 87.81% of its industry peers.
The Return On Equity of ALNY (-414.62%) is worse than 77.39% of its industry peers.
Industry RankSector Rank
ROA -6.56%
ROE -414.62%
ROIC N/A
ROA(3y)-16.65%
ROA(5y)-19.71%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALNY Yearly ROA, ROE, ROICALNY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 -400 600

1.3 Margins

ALNY's Gross Margin of 85.62% is amongst the best of the industry. ALNY outperforms 87.81% of its industry peers.
ALNY's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for ALNY so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 85.62%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.88%
GM growth 5Y-0.68%
ALNY Yearly Profit, Operating, Gross MarginsALNY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

4

2. Health

2.1 Basic Checks

ALNY does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ALNY has been increased compared to 1 year ago.
The number of shares outstanding for ALNY has been increased compared to 5 years ago.
Compared to 1 year ago, ALNY has an improved debt to assets ratio.
ALNY Yearly Shares OutstandingALNY Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
ALNY Yearly Total Debt VS Total AssetsALNY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

2.2 Solvency

An Altman-Z score of 3.29 indicates that ALNY is not in any danger for bankruptcy at the moment.
With a decent Altman-Z score value of 3.29, ALNY is doing good in the industry, outperforming 76.68% of the companies in the same industry.
ALNY has a Debt/Equity ratio of 15.27. This is a high value indicating a heavy dependency on external financing.
ALNY's Debt to Equity ratio of 15.27 is on the low side compared to the rest of the industry. ALNY is outperformed by 84.98% of its industry peers.
Industry RankSector Rank
Debt/Equity 15.27
Debt/FCF N/A
Altman-Z 3.29
ROIC/WACCN/A
WACC9.98%
ALNY Yearly LT Debt VS Equity VS FCFALNY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B 1.5B

2.3 Liquidity

ALNY has a Current Ratio of 2.78. This indicates that ALNY is financially healthy and has no problem in meeting its short term obligations.
ALNY has a worse Current ratio (2.78) than 67.31% of its industry peers.
A Quick Ratio of 2.71 indicates that ALNY has no problem at all paying its short term obligations.
ALNY has a worse Quick ratio (2.71) than 66.25% of its industry peers.
Industry RankSector Rank
Current Ratio 2.78
Quick Ratio 2.71
ALNY Yearly Current Assets VS Current LiabilitesALNY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

More info and screens

7

3. Growth

3.1 Past

ALNY shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 39.04%, which is quite impressive.
Looking at the last year, ALNY shows a very strong growth in Revenue. The Revenue has grown by 22.97%.
ALNY shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 59.21% yearly.
EPS 1Y (TTM)39.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40.91%
Revenue 1Y (TTM)22.97%
Revenue growth 3Y38.61%
Revenue growth 5Y59.21%
Sales Q2Q%34.9%

3.2 Future

Based on estimates for the next years, ALNY will show a very strong growth in Earnings Per Share. The EPS will grow by 63.18% on average per year.
The Revenue is expected to grow by 27.60% on average over the next years. This is a very strong growth
EPS Next Y18.92%
EPS Next 2Y53.11%
EPS Next 3Y66.99%
EPS Next 5Y63.18%
Revenue Next Year29.99%
Revenue Next 2Y27.5%
Revenue Next 3Y28.16%
Revenue Next 5Y27.6%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ALNY Yearly Revenue VS EstimatesALNY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2B 4B 6B 8B 10B
ALNY Yearly EPS VS EstimatesALNY Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 10 20

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ALNY reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALNY. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALNY Price Earnings VS Forward Price EarningsALNY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 -100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALNY Per share dataALNY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

ALNY's earnings are expected to grow with 66.99% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y53.11%
EPS Next 3Y66.99%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ALNY!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALNYLAM PHARMACEUTICALS INC

NASDAQ:ALNY (4/28/2025, 5:58:22 PM)

After market: 254.85 0 (0%)

254.85

+3.29 (+1.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-13 2025-02-13/bmo
Earnings (Next)05-01 2025-05-01/bmo
Inst Owners96.57%
Inst Owner Change0.49%
Ins Owners0.38%
Ins Owner Change11.44%
Market Cap33.15B
Analysts78.46
Price Target324.18 (27.2%)
Short Float %2.4%
Short Ratio3.08
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.9%
Min EPS beat(2)-2.21%
Max EPS beat(2)4%
EPS beat(4)3
Avg EPS beat(4)36.72%
Min EPS beat(4)-2.21%
Max EPS beat(4)88.19%
EPS beat(8)6
Avg EPS beat(8)39.21%
EPS beat(12)7
Avg EPS beat(12)19.17%
EPS beat(16)9
Avg EPS beat(16)12.2%
Revenue beat(2)0
Avg Revenue beat(2)-4.13%
Min Revenue beat(2)-7.88%
Max Revenue beat(2)-0.39%
Revenue beat(4)2
Avg Revenue beat(4)12.7%
Min Revenue beat(4)-7.88%
Max Revenue beat(4)45.66%
Revenue beat(8)4
Avg Revenue beat(8)16.17%
Revenue beat(12)5
Avg Revenue beat(12)7.93%
Revenue beat(16)8
Avg Revenue beat(16)6.44%
PT rev (1m)2.5%
PT rev (3m)4.85%
EPS NQ rev (1m)9.25%
EPS NQ rev (3m)-44.82%
EPS NY rev (1m)-2.7%
EPS NY rev (3m)-40.61%
Revenue NQ rev (1m)1.34%
Revenue NQ rev (3m)5.8%
Revenue NY rev (1m)0.64%
Revenue NY rev (3m)8.37%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 14.75
P/FCF N/A
P/OCF N/A
P/B 494.14
P/tB 494.14
EV/EBITDA N/A
EPS(TTM)-2.17
EYN/A
EPS(NY)-1.76
Fwd EYN/A
FCF(TTM)-0.33
FCFYN/A
OCF(TTM)-0.06
OCFYN/A
SpS17.28
BVpS0.52
TBVpS0.52
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -6.56%
ROE -414.62%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 85.62%
FCFM N/A
ROA(3y)-16.65%
ROA(5y)-19.71%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.88%
GM growth 5Y-0.68%
F-Score5
Asset Turnover0.53
Health
Industry RankSector Rank
Debt/Equity 15.27
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 60.49%
Cap/Sales 1.52%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.78
Quick Ratio 2.71
Altman-Z 3.29
F-Score5
WACC9.98%
ROIC/WACCN/A
Cap/Depr(3y)112.53%
Cap/Depr(5y)140.08%
Cap/Sales(3y)3.96%
Cap/Sales(5y)7.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)39.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40.91%
EPS Next Y18.92%
EPS Next 2Y53.11%
EPS Next 3Y66.99%
EPS Next 5Y63.18%
Revenue 1Y (TTM)22.97%
Revenue growth 3Y38.61%
Revenue growth 5Y59.21%
Sales Q2Q%34.9%
Revenue Next Year29.99%
Revenue Next 2Y27.5%
Revenue Next 3Y28.16%
Revenue Next 5Y27.6%
EBIT growth 1Y37.3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year161.95%
EBIT Next 3Y128.15%
EBIT Next 5Y130.16%
FCF growth 1Y-201.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-107.98%
OCF growth 3YN/A
OCF growth 5YN/A